WASPSS: A Clinical Decision Support System for Antimicrobial Stewardship

The increase of infections caused by resistant bacteria has become one of the major health-care problems worldwide. The creation of multidisciplinary teams dedicated to the implementation of antimicrobial stewardship programmes (ASPs) is encouraged by all clinical institutions to cope with this problem. In this chapter, we describe the Wise Antimicrobial Stewardship Program Support System (WASPSS), a CDSS focused on providing support for ASP teams. WASPSS gathers the required information from other hospital systems in order to provide decision support in antimicrobial stewardship from both patient-centered and global perspectives. To achieve this, it combines business intelligence techniques with a rule-based inference engine to integrate the data and knowledge required in this scenario. The system provides functions such as alerts, recommendations, antimicrobial prescription support and global surveillance. Furthermore, it includes experimental modules for improving the adoption of clinical guidelines and applying prediction models related with antimicrobial resistance. All these functionalities are provided through a multi-user web interface, personalized for each role of the ASP team

Developmental roadmap for antimicrobial susceptibility testing systems

Antimicrobial susceptibility testing (AST) technologies help to accelerate the initiation of targeted antimicrobial therapy for patients with infections and could potentially extend the lifespan of current narrow-spectrum antimicrobials. Although conceptually new and rapid AST technologies have been described, including new phenotyping methods, digital imaging and genomic approaches, there is no single major, or broadly accepted, technological breakthrough that leads the field of rapid AST platform development. This might be owing to several barriers that prevent the timely development and implementation of novel and rapid AST platforms in health-care settings. In this Consensus Statement, we explore such barriers, which include the utility of new methods, the complex process of validating new technology against reference methods beyond the proof-of-concept phase, the legal and regulatory landscapes, costs, the uptake of new tools, reagent stability, optimization of target product profiles, difficulties conducting clinical trials and issues relating to quality and quality control, and present possible solutions

Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently Used Methods

Antimicrobial resistance (AMR) has emerged as a major threat to public health globally. Accurate and rapid detection of resistance to antimicrobial drugs, and subsequent appropriate antimicrobial treatment, combined with antimicrobial stewardship, are essential for controlling the emergence and spread of AMR. This article reviews common antimicrobial susceptibility testing (AST) methods and relevant issues concerning the advantages and disadvantages of each method. Although accurate, classic technologies used in clinical microbiology to profile antimicrobial susceptibility are time-consuming and relatively expensive. As a result, physicians often prescribe empirical antimicrobial therapies and broad-spectrum antibiotics. Although recently developed AST systems have shown advantages over traditional methods in terms of testing speed and the potential for providing a deeper insight into resistance mechanisms, extensive validation is required to translate these methodologies to clinical practice. With a continuous increase in antimicrobial resistance, additional efforts are needed to develop innovative, rapid, accurate, and portable diagnostic tools for AST. The wide implementation of novel devices would enable the identification of the optimal treatment approaches and the surveillance of antibiotic resistance in health, agriculture, and the environment, allowing monitoring and better tackling the emergence of AMR

Antibiotic Resistance and Prescribing in Children Hospitalized with Community-Acquired Pneumonia

Pneumonia causes more deaths in children under 5 years old worldwide than malaria, AIDS and measles combined. Community-acquired pneumonia occurs annually in about 4 million children under 5 years old in the United States and is typically caused by Streptococcus pneumoniae. Substantial variability exists in the management of this disease. The variability in the management of pediatric pneumonia is due to all aspects of the disease, including but not limited to the numerous agents that cause the disease, the lack of a gold standard diagnostic test and the lack of national guidelines regarding treatment. This variability in treatment has resulted in the use of unnecessarily broad spectrum antibiotics leading to more resistant organisms becoming more prevalent in the community. The prevalence of penicillin resistance in S. pneumoniae has increased over the past decade, but penicillin is found to be still effective clinically in treating nonsusceptible pneumococci. Accredited hospitals in the U.S. document antibiotic susceptibility patterns of S. pneumoniae and it is unclear whether the hospital-reported susceptibility patterns influence the clinician's prescribing patterns. It is also unknown if prescribing broader spectrum antibiotics to patients have similar outcomes to patients who are prescribed narrower spectrum antibiotics, for instance penicillin alone. This research examines the variability that exists in managing pediatric pneumonia by using existing data from 20,000 patients collected from over 30 tertiary care children's hospitals across the United States.Ph.D., Epidemiology -- Drexel University, 201

Pilot study on the current management of children with COVID-19 in hospitals in Bangladesh; findings and implications

Objective: The focus on COVID-19 in children in low- and middle-income countries including Bangladesh has been on addressing key issues including poor vaccination rates as well as mental health issues, domestic violence and child labour. However, the focus on optimally managing children in hospitals is changing with new variants and concerns with the development of hyperinflammatory syndromes. There are also concerns with the overuse of antimicrobials to treat patients with COVID-19 in hospitals enhancing resistance rates. The Bangladesh Paediatric Association have developed guidelines to improve patient care building on national guidance. Consequently, there is a need to document the current management of children with COVID-19 in Bangladesh and use the findings for future guidance. Methods: Rapid analysis of the management of children with COVID-19 among eight private and public hospitals in Bangladesh with varying numbers of in-patient beds using purposely developed case report forms (CRFs). The CRFs were piloted before full roll-out. Results: Overall low numbers of children in hospital with COVID-19 (4.3% of in-patient beds). The majority were male (59.6%) and aged 5 years or under (63.5%). Reasons for admission included respiratory distress/ breathing difficulties with 94.2% of COVID-19 cases confirmed. All children were prescribed antibiotics empirically, typically those on the Watch list of antibiotics and administered parenterally, with only a small minority switched to oral therapy before discharge. There was appreciable prescribing of Vitamins (C and D) and zinc and encouragingly limited prescribing of other antimicrobials (antivirals, antimalarials and antiparasitic medicines). Length of stay was typically 5 to 10 days. Conclusion: Encouraging to see low hospitalisation rates and limited use of antimicrobials apart from antibiotics. Concerns with high empiric use of antibiotics and limited switching to oral formulations can be addressed by instigating antimicrobial stewardship programmes. We will be monitoring this